140 related articles for article (PubMed ID: 1552512)
1. Antimitotic agents. Chiral isomers of ethyl [5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7 -yl]carbamate.
Temple C; Rener GA
J Med Chem; 1992 Mar; 35(6):988-93. PubMed ID: 1552512
[TBL] [Abstract][Full Text] [Related]
2. Antimitotic agents: ring analogues and derivatives of ethyl [(S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7- yl]carbamate.
Temple C; Rener GA
J Med Chem; 1992 Dec; 35(26):4809-12. PubMed ID: 1479582
[TBL] [Abstract][Full Text] [Related]
3. New anticancer agents: chiral isomers of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazine-7-car bamate .
Temple C; Rener GA
J Med Chem; 1989 Sep; 32(9):2089-92. PubMed ID: 2769680
[TBL] [Abstract][Full Text] [Related]
4. Antimitotic agents. Alterations at the 2,3-positions of ethyl (5-amino-1,2-dihydropyrido[3,4-b]pyrazin-7-yl)carbamates.
Temple C; Rener GA; Comber RN; Waud WR
J Med Chem; 1991 Nov; 34(11):3176-81. PubMed ID: 1956035
[TBL] [Abstract][Full Text] [Related]
5. Potential antimitotic agents. Synthesis of some ethyl benzopyrazin-7-ylcarbamates, ethyl pyrido[3,4-b]pyrazin-7-ylcarbamates, and ethyl pyrido[3,4-e]-as-triazin-7-ylcarbamates.
Temple C; Rener GA
J Med Chem; 1990 Nov; 33(11):3044-50. PubMed ID: 2231603
[TBL] [Abstract][Full Text] [Related]
6. New anticancer agents: alterations of the carbamate group of ethyl (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)car bamates.
Temple C; Rener GA; Comber RN
J Med Chem; 1989 Oct; 32(10):2363-7. PubMed ID: 2795608
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of ethyl 5-amino-2-methyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl carbamate analogs modified at position C2 on tubulin polymerization, binding, and conformational changes.
Barbier P; Peyrot V; Sarrazin M; Rener GA; Briand C
Biochemistry; 1995 Dec; 34(51):16821-9. PubMed ID: 8527458
[TBL] [Abstract][Full Text] [Related]
8. New anticancer agents: synthesis of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines).
Temple C; Wheeler GP; Elliott RD; Rose JD; Kussner CL; Comber RN; Montgomery JA
J Med Chem; 1982 Sep; 25(9):1045-50. PubMed ID: 7131483
[TBL] [Abstract][Full Text] [Related]
9. The active GTP- and ground GDP-liganded states of tubulin are distinguished by the binding of chiral isomers of ethyl 5-amino-2-methyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl carbamate.
Barbier P; Peyrot V; Leynadier D; Andreu JM
Biochemistry; 1998 Jan; 37(2):758-68. PubMed ID: 9425100
[TBL] [Abstract][Full Text] [Related]
10. Antimitotic agents: structure-activity studies with some pyridine derivatives.
Temple C; Rener GA; Waud WR; Noker PE
J Med Chem; 1992 Oct; 35(20):3686-90. PubMed ID: 1433180
[TBL] [Abstract][Full Text] [Related]
11. Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.
Waud WR; Harrison SD; Temple CG; Griswold DP
Cancer Chemother Pharmacol; 1992; 29(3):190-4. PubMed ID: 1733551
[TBL] [Abstract][Full Text] [Related]
12. 1,2-Dihydropyrido[3,4-b]pyrazines: structure-activity relationships.
Temple C; Wheeler GP; Elliott RD; Rose JD; Comber RN; Montgomery JA
J Med Chem; 1983 Jan; 26(1):91-5. PubMed ID: 6827530
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of potential anticancer agents. Pyrido[4,3-b][1,4]oxazines and pyrido[4,3-b][1,4]thiazines.
Temple C; Wheeler GP; Comber RN; Elliott RD; Montgomery JA
J Med Chem; 1983 Nov; 26(11):1614-9. PubMed ID: 6631917
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.
Waud WR; Leopold WR; Elliott WL; Dykes DJ; Laster WR; Temple CG; Harrison SD; Griswold DP
Cancer Res; 1990 Jun; 50(11):3239-44. PubMed ID: 2334919
[TBL] [Abstract][Full Text] [Related]
15. 1-Amino-substituted 4-methyl-5H-pyrido[3',4':4,5]pyrrolo[3,2-c]pyridines: a new class of antineoplastic agents.
Nguyen CH; Bisagni E; Pepin O; Pierré A; de Cointet P
J Med Chem; 1987 Sep; 30(9):1642-7. PubMed ID: 3625709
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.
de Ines C; Leynadier D; Barasoain I; Peyrot V; Garcia P; Briand C; Rener GA; Temple C
Cancer Res; 1994 Jan; 54(1):75-84. PubMed ID: 8261466
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-[(N-methylanilino)methyl]-pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928).
Wheeler GP; Bowdon BJ; Werline JA; Adamson DJ; Temple CG
Cancer Res; 1982 Mar; 42(3):791-8. PubMed ID: 7059977
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 5-benzyl-2-phenylpyrazolo[1,5-a]pyrazin-4,6(5H,7H)-dione derivatives and discovery of an apoptosis inducer for H322 lung cancer cells.
Lv HS; Kong XQ; Ming QQ; Jin X; Miao JY; Zhao BX
Bioorg Med Chem Lett; 2012 Jan; 22(2):844-9. PubMed ID: 22209459
[TBL] [Abstract][Full Text] [Related]
19. Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias.
Cholody WM; Martelli S; Konopa J
J Med Chem; 1992 Jan; 35(2):378-82. PubMed ID: 1732555
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of 9-O-substituted derivatives of 9-hydroxy-5, 6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10- and 11-methyl analogues with improved antitumor activity.
Guillonneau C; PierréA ; Charton Y; Guilbaud N; Kraus-Berthier L; Léonce S; Michel A; Bisagni E; Atassi G
J Med Chem; 1999 Jun; 42(12):2191-203. PubMed ID: 10377224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
